Oruka Therapeutics, Inc.

ORKA ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010
Operating Activities
Net Income $-18.5M $-16.4M $-11.4M $-9.7M $-6.9M $-4.3M $-5.4M $-8.4M
Depreciation & Amortization $27.0K $24.0K $19.0K $12.0K $26.0K $43.0K $602.0K $338.0K
Depreciation
Amortization
Stock-Based Compensation $458.0K $576.0K $599.0K $647.0K $283.0K $306.0K $308.0K $458.0K
Net Cash from Operating Activities $-17.5M $-15.0M $-10.5M $-9.4M $-5.3M $-4.1M $-7.0M $-8.3M
Investing Activities
Capital Expenditures $3.0K $12.0K $11.0K $19.0K $32.0K $19.0K $4.0K
Business Acquisitions
Net Cash from Investing Activities $12.9M $-32.0K $2.0M $265.0K
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $5.8M $19.2M $1.1M $3.9M $7.3M
Net Change in Cash $1.3M $-1.4M $13.8M $-3.0M $-1.1M $-738.0K
Free Cash Flow $-17.5M $-15.0M $-10.5M $-9.4M $-5.3M $-7.0M $-8.3M
← Newer Page 2 of 2 Older →